ANXA5 and neoplasm: In contrast to cisplatin and 5-FU treated cells, epirubicin-treated cells did not recover when the drug was removed from the medium, corresponding with the annexin V-PE results, suggesting that the level of change in 18FDG incorporation is predictive of tumour cell response.